JP6431670B2 - 筋肉疲労の回復を促進するためのアミノ酸含有組成物 - Google Patents
筋肉疲労の回復を促進するためのアミノ酸含有組成物 Download PDFInfo
- Publication number
- JP6431670B2 JP6431670B2 JP2013527986A JP2013527986A JP6431670B2 JP 6431670 B2 JP6431670 B2 JP 6431670B2 JP 2013527986 A JP2013527986 A JP 2013527986A JP 2013527986 A JP2013527986 A JP 2013527986A JP 6431670 B2 JP6431670 B2 JP 6431670B2
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- amino acid
- containing composition
- recovery
- damage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001413 amino acids Chemical class 0.000 title claims description 92
- 239000000203 mixture Substances 0.000 title claims description 66
- 238000011084 recovery Methods 0.000 title claims description 38
- 206010049565 Muscle fatigue Diseases 0.000 title claims description 34
- 230000001737 promoting effect Effects 0.000 title claims description 15
- 229940024606 amino acid Drugs 0.000 claims description 93
- 208000029549 Muscle injury Diseases 0.000 claims description 41
- 210000003205 muscle Anatomy 0.000 claims description 39
- 230000008602 contraction Effects 0.000 claims description 26
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 19
- 102100036912 Desmin Human genes 0.000 claims description 16
- 108010044052 Desmin Proteins 0.000 claims description 16
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 15
- 208000000112 Myalgia Diseases 0.000 claims description 14
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 208000013465 muscle pain Diseases 0.000 claims description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 9
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 9
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 9
- 239000004473 Threonine Substances 0.000 claims description 9
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 9
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 9
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 9
- 229960000310 isoleucine Drugs 0.000 claims description 9
- 229930182817 methionine Natural products 0.000 claims description 9
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 9
- 239000004474 valine Substances 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 208000010428 Muscle Weakness Diseases 0.000 claims description 5
- 206010028372 Muscular weakness Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000700159 Rattus Species 0.000 description 18
- -1 and the like Chemical class 0.000 description 12
- 235000013305 food Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000000663 muscle cell Anatomy 0.000 description 6
- 210000003365 myofibril Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 150000003839 salts Chemical group 0.000 description 6
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 5
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000004118 muscle contraction Effects 0.000 description 5
- 230000003387 muscular Effects 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000020931 dietary conditions Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000015004 muscle tenderness Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 210000004345 peroneal nerve Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 235000021568 protein beverage Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Description
すなわち、本発明は以下の通りである。
当該(1)〜(9)のアミノ酸の総含有量に対する各アミノ酸の含有量のモル組成比が下記の数値範囲内である、
筋肉疲労の回復促進用アミノ酸含有組成物。
(1)ロイシン 35〜66%
(2)イソロイシン 5.0〜15%
(3)バリン 5.0〜15%
(4)スレオニン 7.0〜14%
(5)リジン 8.0〜16%
(6)メチオニン 2.0〜10%
(7)ヒスチジン 0.1〜3.5%
(8)フェニルアラニン 2.5〜8.0%
(9)トリプトファン 0.1〜2.0%
[2]筋肉疲労が、筋損傷に起因する筋肉疲労である、上記[1]記載のアミノ酸含有組成物。
[3]筋損傷が、運動後の筋損傷である、上記[2]記載のアミノ酸含有組成物。
[4]運動後の筋損傷が、伸張性収縮運動後の筋損傷である、上記[3]記載のアミノ酸含有組成物。
[5]筋肉疲労の回復促進が、筋肉痛の予防及び/又は改善である、上記[1]記載のアミノ酸含有組成物。
[6]筋肉疲労の回復促進が、筋力低下の予防及び/又は改善である、上記[1]記載のアミノ酸含有組成物。
[7]筋肉疲労の回復促進が、筋損傷の予防及び/又は改善である、上記[1]記載のアミノ酸含有組成物。
[8]下記の(1)〜(9)のアミノ酸を含み、当該(1)〜(9)のアミノ酸の総含有量に対する各アミノ酸の含有量のモル組成比が下記の数値範囲内であるアミノ酸含有組成物を、有効量投与することを特徴とする、筋肉疲労の回復促進方法。
(1)ロイシン 35〜66%
(2)イソロイシン 5.0〜15%
(3)バリン 5.0〜15%
(4)スレオニン 7.0〜14%
(5)リジン 8.0〜16%
(6)メチオニン 2.0〜10%
(7)ヒスチジン 0.1〜3.5%
(8)フェニルアラニン 2.5〜8.0%
(9)トリプトファン 0.1〜2.0%
[9]下記の(1)〜(9)のアミノ酸を含み、当該(1)〜(9)のアミノ酸の総含有量に対する各アミノ酸の含有量のモル組成比が下記の数値範囲内であるアミノ酸含有組成物の、筋肉疲労の回復促進剤を製造するための使用。
(1)ロイシン 35〜66%
(2)イソロイシン 5.0〜15%
(3)バリン 5.0〜15%
(4)スレオニン 7.0〜14%
(5)リジン 8.0〜16%
(6)メチオニン 2.0〜10%
(7)ヒスチジン 0.1〜3.5%
(8)フェニルアラニン 2.5〜8.0%
(9)トリプトファン 0.1〜2.0%
本発明のアミノ酸含有組成物を摂取することにより、過度の運動負荷により損傷した筋原繊維タンパク質、筋原繊維や筋細胞膜に結合する細胞骨格タンパク質、および細胞外マトリクスの合成を促進し、筋損傷の回復を促進することができる。
また、本発明のアミノ酸含有組成物を摂取することにより、筋肉痛、筋力低下を予防及び/又は改善することができる。
摂取期間も、筋肉疲労の程度、年齢、性別、体重、食事の状況などに基づき、個別に定められるが、通常1日〜2週間であり、好ましくは5日〜1週間である。
すなわち、筋肉をホモジナイズした後に、SDS-PAGEでタンパク質を分画、転写膜に転写し、その後、デスミン抗体を用いたウエスタンブロットによって、定量する。
具体的には、筋損傷とは、筋肉中のデスミンタンパク質の量が、安静時よりも低い状態をいう。
1.アミノ酸含有組成物A
表1に示す組成となるように各種のアミノ酸の所定量を秤量の後、混合し、アミノ酸含有組成物Aを得た。
8週齢のWistar系雌性ラットを用いて、トレッドミルダウンヒル走を行い、筋損傷モデルラットを作出した。トレッドミルダウンヒル走は、傾斜角度を−13.5°とし、17m/minの速度で5分間走らせた後、2分間休ませる運動を1セットとして、これを26セット行った。筋損傷モデルラットの筋肉中のデスミンタンパク質量の経時変化を図1に示す。
10週齢のSD系雄性ラットを用いて、1g/kgの用量のアミノ酸含有組成物A、又は水を経口投与し、当該経口投与の30分後に、伸張性収縮負荷を行い、筋損傷を誘発させた。
伸張性収縮負荷は、ペントバルビタール麻酔下にて、ラットの総骨腓骨神経近傍に陰極、坐骨神経近傍に陽極を差込み、単収縮閾値の3倍の電流値にて50Hzで電気刺激を与えて1秒間筋収縮させ、同時に、筋収縮と逆方向へ足をモーターで牽引し、その後3秒間の休ませる運動を1セットとし、これを500セット繰り返すことにより行った。当該伸張性収縮負荷による、ラットの筋肉中のデスミンタンパク質量の経時変化を図2に示す。
伸張性収縮負荷の2時間後に、再び1g/kgの用量のアミノ酸含有組成物A、又は水を経口投与し、その後、筋肉痛の評価を行った。
筋肉痛の評価は、筋肉の圧痛閾値の経時変化を観察することにより行った。圧痛閾値は、覚醒下のラットの前脛骨筋上に、Randall-Selitto鎮痛計の円錐型プローブ(直径2.6mm)をあて、経皮的に157mN/sの速度で荷重を高めていき、痛みを感じて足を引くタイミングにおける荷重を測定することにより求めた。筋肉痛が発症すると、圧痛閾値は低下する。結果を図3に示す。尚、図3において、圧痛閾値は、伸張性収縮負荷前の圧痛閾値を100%として、これに対する比率(%)で示した。
8週齢のWistar系雌性ラットを用いて、トレッドミルダウンヒル走を行い、筋損傷モデルラットを作出した。トレッドミルダウンヒル走は、傾斜角度を−13.5°とし、17m/minの速度で5分間走らせた後、2分間休ませる運動を1セットとして、これを26セット行った。
トレッドミルダウンヒル走の終了直後に、1g/kgの用量のアミノ酸含有組成物A、又は水を経口投与し、当該経口投与の20分後から50分後までの30分間のデスミンタンパク質及び筋コラーゲンタンパク質の合成速度を、安定同位体標識プロリンを使用した大量投与法により求めた。デスミンタンパク質の合成速度を図4に、筋コラーゲンタンパク質の合成速度を図5に、それぞれ示す。
11週齢のSD系雄性ラットを用いて、1g/kgの用量のアミノ酸含有組成物A、又は水を経口投与し、当該経口投与の30分後に伸張性収縮負荷を行い、筋損傷を誘発させた。
伸張性収縮負荷は、イソフルラン麻酔下にて、ラットの前脛骨筋及び腓骨頭近傍に陰極、前脛骨筋遠位端近傍に陽極を貼付け、4mAの電流値にて50Hzで電気刺激を与えて1秒間筋収縮させ、同時に、筋収縮と逆方向へ足をモーターで牽引し、その後3秒間の休ませる運動を1セットとし、これを500セット繰り返すことにより行った。
伸張性収縮負荷の1時間後に、再び1g/kgの用量のアミノ酸含有組成物A、又は水を経口投与し、当該経口投与の24時間後に、筋肉を採取した。
筋損傷の評価は、伸張性収縮負荷直前のラットに、0.5%エバンスブルーダイ(以下、「EBD」と略記する)を、10ml/kg用量で腹腔内に投与しておき、その後、伸張性収縮負荷を施したラットから採取した筋肉をKOHによって溶解し、筋肉内のEBD量を測定することにより行った。EBDは、筋損傷が激しいほど、筋肉に多く取り込まれることから、筋肉内に取り込まれたEBD量を測定することによって、筋肉の損傷度合いを評価可能である。伸張性収縮負荷を施したラットから採取した筋肉中のEBD量を、図6に示す。図6においてEBD量は、水投与群を100%として、これに対する比率(%)で示した。
11〜12週齢のSD系雄性ラットを用いて、1g/kgの用量のアミノ酸含有組成物A、又は水を経口投与し、当該経口投与の30分後に伸張性収縮負荷を行い、筋損傷を誘発させた。
伸張性収縮負荷は、イソフルラン麻酔下にて、ラットの前脛骨筋及び腓骨頭近傍に陰極、前脛骨筋遠位端近傍に陽極を貼付け、4mAの電流値にて50Hzで電気刺激を与えて1秒間筋収縮させ、同時に、筋収縮と逆方向へ足をモーターで牽引し、その後3秒間の休ませる運動を1セットとし、これを500セット繰り返すことにより行った。
伸張性収縮負荷の1時間後に、再び1g/kgの用量のアミノ酸含有組成物Aを経口投与し、その後、伸張性収縮負荷の6時間後に筋力測定を行った。
筋力測定は、麻酔下のラットの足に張力計を装着し、上記伸張性収縮負荷と同様に、電極を貼付け、4mAの電流値にて50Hzで電気刺激を与えて、足の背屈時の等尺性筋力を測定することにより行った。伸張性収縮負荷の6時間後の筋力を、図7に示す。図7において筋力の値は、伸張性収縮負荷前の筋力を100%として、これに対する比率(%)で示した。
Claims (9)
- 下記の(1)〜(9)のアミノ酸を含み、
当該(1)〜(9)のアミノ酸の総含有量に対する各アミノ酸の含有量のモル組成比が下記の数値範囲内である、
筋肉疲労の回復促進用アミノ酸含有組成物。
(1)ロイシン 35〜66%
(2)イソロイシン 5.0〜15%
(3)バリン 5.0〜15%
(4)スレオニン 7.0〜14%
(5)リジン 8.0〜16%
(6)メチオニン 2.0〜10%
(7)ヒスチジン 0.1〜3.5%
(8)フェニルアラニン 2.5〜8.0%
(9)トリプトファン 0.1〜2.0% - 筋肉疲労が、筋損傷に起因する筋肉疲労である、請求項1記載のアミノ酸含有組成物。
- 筋損傷が、運動後の筋損傷である、請求項2記載のアミノ酸含有組成物。
- 運動後の筋損傷が、伸張性収縮運動後の筋損傷である、請求項3記載のアミノ酸含有組成物。
- 筋肉疲労の回復促進が、筋肉痛の予防及び/又は改善である、請求項1記載のアミノ酸含有組成物。
- 筋肉疲労の回復促進が、筋力低下の予防及び/又は改善である、請求項1記載のアミノ酸含有組成物。
- 筋肉疲労の回復促進が、筋損傷の予防及び/又は改善である、請求項1記載のアミノ酸含有組成物。
- 筋損傷の予防及び/又は改善が、デスミンタンパク質及び/又は筋コラーゲンタンパク質の合成促進である、請求項7記載のアミノ酸含有組成物。
- 下記の(1)〜(9)のアミノ酸を含み、当該(1)〜(9)のアミノ酸の総含有量に対する各アミノ酸の含有量のモル組成比が下記の数値範囲内であるアミノ酸含有組成物の、筋肉疲労の回復促進剤を製造するための使用。
(1)ロイシン 35〜66%
(2)イソロイシン 5.0〜15%
(3)バリン 5.0〜15%
(4)スレオニン 7.0〜14%
(5)リジン 8.0〜16%
(6)メチオニン 2.0〜10%
(7)ヒスチジン 0.1〜3.5%
(8)フェニルアラニン 2.5〜8.0%
(9)トリプトファン 0.1〜2.0%
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013527986A JP6431670B2 (ja) | 2011-08-08 | 2012-08-01 | 筋肉疲労の回復を促進するためのアミノ酸含有組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011173002 | 2011-08-08 | ||
JP2011173002 | 2011-08-08 | ||
PCT/JP2012/069569 WO2013021891A1 (ja) | 2011-08-08 | 2012-08-01 | 筋肉疲労の回復を促進するためのアミノ酸含有組成物 |
JP2013527986A JP6431670B2 (ja) | 2011-08-08 | 2012-08-01 | 筋肉疲労の回復を促進するためのアミノ酸含有組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2013021891A1 JPWO2013021891A1 (ja) | 2015-03-05 |
JP6431670B2 true JP6431670B2 (ja) | 2018-11-28 |
Family
ID=47668401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013527986A Active JP6431670B2 (ja) | 2011-08-08 | 2012-08-01 | 筋肉疲労の回復を促進するためのアミノ酸含有組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11077081B2 (ja) |
EP (1) | EP2742938B1 (ja) |
JP (1) | JP6431670B2 (ja) |
BR (1) | BR112014002779A2 (ja) |
WO (1) | WO2013021891A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6753775B2 (ja) * | 2013-04-15 | 2020-09-09 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 電気筋肉刺激と組み合わせられるホエータンパク質の使用 |
EP3738590A1 (en) * | 2013-07-31 | 2020-11-18 | Leeds Beckett University | Dietary supplement comprising amino acids for the treatment of sarcopenia |
EP3115047B1 (en) | 2014-03-07 | 2020-05-06 | Ajinomoto Co., Inc. | Debility preventative |
WO2018043694A1 (ja) * | 2016-09-02 | 2018-03-08 | 味の素株式会社 | 筋持久力向上用組成物 |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
CN111295187A (zh) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | 用于治疗肝脏疾病的氨基酸组合物 |
AR115585A1 (es) | 2018-06-20 | 2021-02-03 | Axcella Health Inc | Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo |
US11412771B2 (en) * | 2019-04-12 | 2022-08-16 | The Amino Company LLC | Composition to improve athletic performance by supporting muscle protein synthesis and mental focus |
JP2020176100A (ja) * | 2019-04-22 | 2020-10-29 | 株式会社明治 | 運動誘発性筋損傷を抑制するための組成物 |
CN111528484A (zh) * | 2020-05-08 | 2020-08-14 | 大连医诺生物股份有限公司 | 一种促运动后疲劳恢复的组合物、其制备方法及应用 |
CN111543642A (zh) * | 2020-05-08 | 2020-08-18 | 大连医诺生物股份有限公司 | 一种促耐力运动后增肌的组合物、其制备方法及应用 |
JP2022040051A (ja) | 2020-08-27 | 2022-03-10 | ユニテックフーズ株式会社 | 筋損傷回復促進用組成物 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3617102B2 (ja) * | 1995-01-27 | 2005-02-02 | 味の素株式会社 | ヒト筋肉疲労の早期回復効果を有するアミノ酸栄養組成物 |
JP4280310B2 (ja) * | 1995-08-10 | 2009-06-17 | 佐々木化学工業株式会社 | アミノ酸組成剤 |
WO1997025060A1 (fr) | 1996-01-09 | 1997-07-17 | The Institute Of Physical And Chemical Research | Compositions d'acides amines |
TW413633B (en) * | 1996-01-09 | 2000-12-01 | Rikagaku Kenkyusho | Amino acid composition |
US5716926A (en) * | 1996-07-26 | 1998-02-10 | Paxton K. Beale | Composition of pyruvate and protein and method for increasing protein concentration in a mammal |
US5817329A (en) * | 1997-02-28 | 1998-10-06 | Gardiner; Paul T. | Nutritional supplement for increased muscle size and strength for body builders |
AU1409299A (en) | 1997-11-13 | 1999-06-07 | University Of Florida | Use of ketoacids together with amino acids for enhancing muscle performance and recovery from fatigue |
JP2000026290A (ja) * | 1998-07-07 | 2000-01-25 | Crescendo Corporation:Kk | 分岐鎖アミノ酸による筋力維持 |
US20040087490A1 (en) * | 2002-09-20 | 2004-05-06 | Troup John P. | Nutritional compositions |
CA2529317A1 (en) * | 2003-06-26 | 2004-12-29 | Donald M. Mcleod | Supplement for restoring growth hormone levels |
JP2005040117A (ja) * | 2003-07-24 | 2005-02-17 | Yoshiyuki Fukuda | 食品組成物 |
US20050265990A1 (en) * | 2004-06-01 | 2005-12-01 | Shawn Talbott | Treatments and nutritional supplements for assisting post-exercise recovery |
JP4792730B2 (ja) * | 2004-11-12 | 2011-10-12 | 味の素株式会社 | 抗疲労組成物 |
EP1865944B1 (en) | 2005-03-29 | 2018-08-29 | Ajinomoto Co., Inc. | Amino acid-containing composition used for preventing or remedying decrease in skeletal muscle mass of aged people, comprising L-leucine |
JPWO2006134752A1 (ja) * | 2005-06-15 | 2009-01-08 | 不二製油株式会社 | 大豆ペプチド組成物 |
US20080317886A1 (en) | 2005-11-03 | 2008-12-25 | Sparkman Dennis R | Compositions for Preventing and Reducing Delayed Onset Muscle Soreness |
WO2008123033A1 (ja) | 2007-03-26 | 2008-10-16 | Fuji Oil Company, Limited | 分岐鎖アミノ酸高含有の蛋白質分解物の製造法 |
JP4784910B2 (ja) | 2007-07-03 | 2011-10-05 | 味の素株式会社 | タンパク飲料のアミノ酸含有組成物によるコク味付与または増強方法 |
JP5668271B2 (ja) * | 2008-12-25 | 2015-02-12 | ユーハ味覚糖株式会社 | シスチン−アミノ酸複合体及びその製造方法 |
JP5358619B2 (ja) | 2011-06-13 | 2013-12-04 | 任天堂株式会社 | 無線通信ゲームシステム、ゲーム装置、ゲームプログラムおよび無線通信方法 |
-
2012
- 2012-08-01 JP JP2013527986A patent/JP6431670B2/ja active Active
- 2012-08-01 BR BR112014002779A patent/BR112014002779A2/pt not_active Application Discontinuation
- 2012-08-01 EP EP12822090.2A patent/EP2742938B1/en active Active
- 2012-08-01 WO PCT/JP2012/069569 patent/WO2013021891A1/ja active Application Filing
-
2014
- 2014-02-07 US US14/175,154 patent/US11077081B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11077081B2 (en) | 2021-08-03 |
US20140155448A1 (en) | 2014-06-05 |
WO2013021891A1 (ja) | 2013-02-14 |
EP2742938A1 (en) | 2014-06-18 |
EP2742938B1 (en) | 2018-05-09 |
BR112014002779A2 (pt) | 2017-02-21 |
JPWO2013021891A1 (ja) | 2015-03-05 |
EP2742938A4 (en) | 2015-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6431670B2 (ja) | 筋肉疲労の回復を促進するためのアミノ酸含有組成物 | |
JP5983601B2 (ja) | 栄養組成物 | |
ES2622116T3 (es) | Composición nutricional para la estimulación de la síntesis de proteínas musculares | |
US8445466B2 (en) | Stable aqueous compositions comprising amide-protected bioactive creatine species and uses thereof | |
KR20190099243A (ko) | 근육 질환 및 장애를 치료하기 위한 아미노산 조성물 및 방법 | |
EP3115047B1 (en) | Debility preventative | |
US20140295003A1 (en) | Methods for improving health in canines | |
US20210308084A1 (en) | Agent for improving muscle quality | |
US20150050260A1 (en) | Pyrroloquinoline quinone based compositions and uses | |
US10130715B2 (en) | Methods of improving tolerability, pharmacodynamics, and efficacy of β-alanine and use therefor | |
JP6677775B2 (ja) | 筋肉増強剤 | |
JP6848962B2 (ja) | 行動体力向上剤 | |
EP3993789A1 (en) | Compositions and methods using trigonelline and high protein for preventing or treating conditions or disorders in skeletal muscle | |
JP6119969B2 (ja) | 血圧降下用アミノ酸含有組成物 | |
WO2021079987A1 (ja) | 筋質向上剤 | |
US11045437B2 (en) | Composition for improving brain function | |
WO2020045612A1 (ja) | 間欠的持久力向上剤または血中pH上昇剤 | |
EP3993790A1 (en) | Compositions and methods using trigonelline and minerals for preventing or treating conditions or disorders in skeletal muscle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150625 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160405 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170118 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170530 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20171012 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171012 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6431670 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |